325 related articles for article (PubMed ID: 23742948)
1. Predictors of anticoagulant treatment in patients with nonvalvular atrial fibrillation: results from atrial fibrillation in Turkey: epidemiologic registry.
Kaya H; Ertaş F; Köroğlu B; Vatan B; Çağlıyan ÇE; Gedik S; Yeter E; Aydin M; Akil MA; Soydinç MS; Ozhan H; Ülgen MS;
Clin Appl Thromb Hemost; 2015 Mar; 21(2):144-8. PubMed ID: 23742948
[TBL] [Abstract][Full Text] [Related]
2. The atrial fibrillation in Turkey: Epidemiologic Registry (AFTER).
Ertas F; Eren NK; Kaya H; Aribas A; Acar G; Kanadasi M; Gedik S; Oylumlu M; Yuksel M; Ulgen MS;
Cardiol J; 2013; 20(4):447-52. PubMed ID: 23677730
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology, anticoagulant treatment and risk of thromboembolism in patients with valvular atrial fibrillation: Results from Atrial Fibrillation in Turkey: Epidemiologic Registry (AFTER).
Kaya H; Ertaş F; Kaya Z; Kahya Eren N; Yüksel M; Köroğlu B; Köse N; Yıldız A; Cimen T; Ulgen MS
Cardiol J; 2014; 21(2):158-62. PubMed ID: 23799558
[TBL] [Abstract][Full Text] [Related]
4. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
[TBL] [Abstract][Full Text] [Related]
5. Real-World Clinical Characteristics and Treatment Patterns of Individuals Aged 80 and Older with Nonvalvular Atrial Fibrillation: Results from the ReAl-life Multicenter Survey Evaluating Stroke Study.
Biteker M; Başaran Ö; Doğan V; Altun İ; Özpamuk Karadeniz F; Tekkesin Aİ; Çakıllı Y; Türkkan C; Hamidi M; Demir V; Gürsoy MO; Tek Öztürk M; Aksan G; Seyis S; Ballı M; Alıcı MH; Bozyel S
J Am Geriatr Soc; 2017 Aug; 65(8):1684-1690. PubMed ID: 28394435
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study.
Clua-Espuny JL; Lechuga-Duran I; Bosch-Princep R; Roso-Llorach A; Panisello-Tafalla A; Lucas-Noll J; López-Pablo C; Queralt-Tomas L; Giménez-Garcia E; González-Rojas N; Gallofré López M
Rev Esp Cardiol (Engl Ed); 2013 Jul; 66(7):545-52. PubMed ID: 24776203
[TBL] [Abstract][Full Text] [Related]
7. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
[TBL] [Abstract][Full Text] [Related]
8. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score.
Lip GY; Skjøth F; Rasmussen LH; Larsen TB
J Am Coll Cardiol; 2015 Apr; 65(14):1385-94. PubMed ID: 25770314
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the impact of warfarin time in therapeutic range on outcomes of patients with atrial fibrillation in Turkey: perspectives from the observational, prospective WATER Registry.
Turk UO; Tuncer E; Alioglu E; Yuksel K; Pekel N; Ozpelit E; Vuran O; Tengiz I
Cardiol J; 2015; 22(5):567-75. PubMed ID: 26100825
[TBL] [Abstract][Full Text] [Related]
10. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic Treatment Following Intracerebral Hemorrhage in Patients With and Without Atrial Fibrillation.
Pennlert J; Asplund K; Carlberg B; Wiklund PG; Wisten A; Åsberg S; Eriksson M
Stroke; 2015 Aug; 46(8):2094-9. PubMed ID: 26159794
[TBL] [Abstract][Full Text] [Related]
12. Non-valvular atrial fibrillation in the elderly; preliminary results from the National AFTER (Atrial Fibrillation in Turkey: Epidemiologic Registry) Study.
Ertas F; Oylumlu M; Akil MA; Acet H; Bilik MZ; Celepkolu T; Yildiz A; Kaya H; Alan S; Ozhan H;
Eur Rev Med Pharmacol Sci; 2013 Apr; 17(8):1012-6. PubMed ID: 23661513
[TBL] [Abstract][Full Text] [Related]
13. Heart Failure and Mortality in Patients With Nonvalvular Atrial Fibrillation Started on Novel Oral Anticoagulant Therapy: A Single-Center Experience.
Sunbul M; Oguz M; Dogan Z; Atas H; Bozbay M; Cincin A; Agirbasli M
Clin Appl Thromb Hemost; 2017 Jul; 23(5):454-459. PubMed ID: 26566667
[TBL] [Abstract][Full Text] [Related]
14. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
Lip GY; Rushton-Smith SK; Goldhaber SZ; Fitzmaurice DA; Mantovani LG; Goto S; Haas S; Bassand JP; Camm AJ; Ambrosio G; Janský P; Al Mahmeed W; Oh S; van Eickels M; Raatikainen P; Steffel J; Oto A; Kayani G; Accetta G; Kakkar AK;
Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2 Suppl 1):S12-20. PubMed ID: 25714828
[TBL] [Abstract][Full Text] [Related]
15. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.
Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Oliveira MM; Mairesse G; Crijns HJ; Simantirakis E; Atar D; Kirchhof P; Vardas P; Tavazzi L; Maggioni AP
Europace; 2014 Mar; 16(3):308-19. PubMed ID: 24351881
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulant and antiplatelet therapy for stroke prevention in atrial fibrillation patients in the clinical practice of a single district hospital in Poland.
Bednarski J; Cieszewska E; Strzelecki A; Filipiak KJ
Kardiol Pol; 2013; 71(12):1260-5. PubMed ID: 23990227
[TBL] [Abstract][Full Text] [Related]
17. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA
J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422
[TBL] [Abstract][Full Text] [Related]
18. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
[TBL] [Abstract][Full Text] [Related]
19. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry.
Wang C; Yang Z; Wang C; Wang Y; Zhao X; Liu L; Wang DZ; Li H; Wang Y
J Stroke Cerebrovasc Dis; 2014; 23(5):1157-63. PubMed ID: 24291013
[TBL] [Abstract][Full Text] [Related]
20. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
